Naringin for Health & Longevity - Quick Reference Sheet

Naringin for Health & Longevity

Created on 07/30/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

Naringin is a natural compound found in citrus fruits, most abundant in grapefruit, that the body converts into active naringenin. Animal and laboratory research suggests it calms inflammation and improves how the body handles fats and sugar, but human evidence is mixed and largely unproven. Its main safety concern is changing how certain medicines are absorbed. (Full Review)

Protocol

Dose
250–500 mg/day
Some regimens up to ~600 mg/day
Timing
With food
Separating from interacting medications matters more than time of day
Frequency
Split dosing (twice daily)
Short half-life (~1–3 h) favors divided doses
Time to effect
Metabolic markers
8–12 weeks
Judge lipid and metabolic changes over weeks, not days

Benefits

Contraindications
  • Transplant recipients or others on narrow-therapeutic-index immunosuppressants
  • Multiple OATP1A2/CYP3A4 substrate medications
  • Pregnancy or breastfeeding
Key Interactions
  • Uptake-transporter substrate drugs (fexofenadine, aliskiren, celiprolol, talinolol, levothyroxine)
  • CYP3A4 substrate drugs (felodipine, simvastatin, atorvastatin)
  • OTC antihistamine fexofenadine
  • Lipid- or glucose-lowering supplements (berberine, red yeast rice, bitter melon)
  • Flavonoid or citrus extracts inhibiting the same transporters

Risk & Side Effects

  • High: Drug-transporter and drug-metabolism interactions
  • Medium:
  • Low: Gastrointestinal discomfort
  • Speculative: Weak estrogen-like activity; excessive transporter or enzyme inhibition at high doses; additive metabolic effects

Monitoring

Marker Target Why
LDL cholesterol < 100 mg/dL (many target < 80) Primary lipid target for the metabolic benefit
Triglycerides < 100 mg/dL Tracks fat-handling improvement
HDL cholesterol > 50 (women) / > 40 (men) mg/dL, ideally > 60 Context for overall lipid response
Fasting glucose 70–85 mg/dL Detects blood-sugar effect
HbA1c < 5.3% Three-month average blood sugar
hs-CRP < 1.0 mg/L (ideally < 0.5) Tracks the anti-inflammatory signal
ALT < 25 U/L (men) / < 20 U/L (women) Screens liver-related effects
Adiponectin (optional) Higher is generally favorable Mechanistic marker moved in the human trial

Cadence: Baseline, again at 8–12 weeks, then every 6–12 months if use continues

Qualitative Assessment

  • Energy levels and daytime fatigue
  • Digestive comfort (to catch any gastrointestinal side effects)
  • Appetite and body-weight trend
  • General sense of well-being